Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study - Scorecard - MDSpire

Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study

  • By

  • Daniele Noviello

  • María Chaparro

  • Chiara Viganò

  • Andreas Blesl

  • Brigida Barberio

  • Henit Yanai

  • Ambrogio Orlando

  • Rocío Ferreiro-Iglesias

  • Cristina Bezzio

  • Alessandra Zilli

  • Tamás Molnár

  • Cristian Gheorghe

  • Francesco Conforti

  • Tommaso Innocenti

  • Simone Saibeni

  • Peter Bossuyt

  • Raquel Oliveira

  • Anna Maria Carvalhas Gabrielli

  • Alessandra Losco

  • Sophie Vieujean

  • Enrico Tettoni

  • Lorena Pirola

  • Silvia Calderone

  • Maya Kornowski Cohen

  • Gabriele Dragoni

  • Timo Rath

  • Manuel Barreiro-de Acosta

  • Edoardo Vincenzo Savarino

  • Javier P Gisbert

  • Maurizio Vecchi

  • Raja Atreya

  • Flavio Caprioli

  • April 1, 2025

  • 0 min

Share

Clinical Scorecard: Efficacy and Safety of Fidaxomicin in Treating Clostridioides difficile Infection Among Inflammatory Bowel Disease Patients: A Multicenter Retrospective Analysis

At a Glance

CategoryDetail
ConditionClostridioides difficile infection (CDI) in patients with inflammatory bowel disease (IBD)
Key MechanismsFidaxomicin as an antimicrobial targeting CDI with potential impact on CDI recurrence and IBD outcomes
Target PopulationAdult patients with ulcerative colitis (UC) or Crohn’s disease (CD) diagnosed with CDI
Care SettingMulticenter referral centers across Europe and Israel, including outpatient and inpatient settings

Key Highlights

  • CDI recurrence rate was 10% at 8 weeks post-fidaxomicin treatment in IBD patients.
  • Sustained response (no CDI therapy within 12 weeks) was achieved in 82% of patients.
  • Fidaxomicin was well tolerated with few mild to moderate adverse events reported.

Guideline-Based Recommendations

Diagnosis

  • Confirm CDI in IBD patients by stool testing using glutamate dehydrogenase antigen, nucleic acid amplification test for toxigenic C. difficile, or toxin enzyme immunoassay.

Management

  • Treat symptomatic IBD patients with confirmed CDI using appropriate antimicrobial therapy.
  • Fidaxomicin for at least 7 consecutive days is effective and safe for CDI treatment in IBD patients.
  • Vancomycin and fidaxomicin are considered equally effective for non-severe CDI per ECCO guidelines.

Monitoring & Follow-up

  • Monitor for CDI recurrence within 8 weeks post-treatment.
  • Assess IBD therapy escalation needs and colectomy rates within 30 to 180 days following CDI treatment.

Risks

  • IBD patients with CDI have increased risk of exacerbations, colectomy, and mortality.
  • Prior CDI episodes may increase risk of recurrence compared to first CDI episode.

Patient & Prescribing Data

96 adult IBD patients (57 UC, 39 CD) treated with fidaxomicin for CDI, mostly on advanced IBD therapy.

Patients with first CDI episode had lower recurrence (4.3%) and higher sustained response (91%) compared to those with previous CDI episodes (16% recurrence, 75% sustained response).

Clinical Best Practices

  • Use fidaxomicin as an effective and safe treatment option for CDI in IBD patients.
  • Consider patient CDI history when evaluating risk of recurrence and treatment response.
  • Monitor IBD disease activity and therapy escalation needs following CDI treatment.
  • Exclude patients with acute severe UC, toxic megacolon, or prior colectomy from fidaxomicin treatment protocols based on study criteria.

References

Original Source(s)

Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study

  • by Daniele Noviello, María Chaparro, Chiara Viganò, Andreas Blesl, Brigida Barberio, Henit Yanai, Ambrogio Orlando, Rocío Ferreiro-Iglesias, Cristina Bezzio, Alessandra Zilli, Tamás Molnár, Cristian Gheorghe, Francesco Conforti, Tommaso Innocenti, Simone Saibeni, Peter Bossuyt, Raquel Oliveira, Anna Maria Carvalhas Gabrielli, Alessandra Losco, Sophie Vieujean, Enrico Tettoni, Lorena Pirola, Silvia Calderone, Maya Kornowski Cohen, Gabriele Dragoni, Timo Rath, Manuel Barreiro-de Acosta, Edoardo Vincenzo Savarino, Javier P Gisbert, Maurizio Vecchi, Raja Atreya, Flavio Caprioli

  • April 1, 2025

Related Content

Link Between Blastocystis Subtypes 3 and 4 and Intestinal Inflammation as Well as Metronidazole Efficacy in Symptomatic Individuals

Urologic malignancy risk with chronic tumor necrosis factor-alpha inhibitor (TNF-I) exposure: a multicenter, retrospective cohort study

Medical Oddities: Essential Oil, Deadly Consequences

A cabinet mix-up, a chatty heart, a violet catheter bag, stressed kids, and tea that won’t save the brain—just another week.